Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Recombinant Human IL12/15-PDL1B Herpes simplex type I oncolytic virus(Vero cell)(Virogin) in Sarcoma: NCT06126510 Clinical Landscape Report 2026
16 October 2026
NCT06126510 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Locally Advanced Malignant Solid Neoplasm: NCT06131398 Clinical Landscape Report 2026
16 October 2026
NCT06131398 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Nivolumab in Metastatic Renal Cell Carcinoma: NCT06132945 Clinical Landscape Report 2026
16 October 2026
NCT06132945 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab tirumotecan in Endometrial Carcinoma: NCT06132958 Clinical Landscape Report 2026
16 October 2026
NCT06132958 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxychloroquine Sulfate in Breast Cancer: CTRI/2023/11/059909 Clinical Landscape Report 2026
16 October 2026
CTRI/2023/11/059909 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DR-30206 in Hepatocellular Carcinoma: NCT06132828 Clinical Landscape Report 2026
16 October 2026
NCT06132828 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Papillary Renal Cell Carcinoma: NCT06146777 Clinical Landscape Report 2026
16 October 2026
NCT06146777 clinical landscape for Papillary Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JNJ-1493 in High grade B-cell lymphoma: NCT06139406 Clinical Landscape Report 2026
16 October 2026
NCT06139406 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LP-284 in Mantle-Cell Lymphoma: NCT06132503 Clinical Landscape Report 2026
16 October 2026
NCT06132503 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ammonium tetrathiomolybdate in Triple Negative Breast Cancer: NCT06134375 Clinical Landscape Report 2026
16 October 2026
NCT06134375 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Triple Negative Breast Cancer: NCT06140576 Clinical Landscape Report 2026
16 October 2026
NCT06140576 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FPI-2053 in Pancreatic Ductal Adenocarcinoma: NCT06147037 Clinical Landscape Report 2026
16 October 2026
NCT06147037 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…